glp-1 bowel obstruction law firm in west virginia The push to make weight-loss drugs more affordable is running into legal limits. Telehealth company Hims & Hers pulled a less expensive oral version of Wegovy after lawsuits from Novo Nordisk and West Virginia revealed as the

With the goal of enhancing patient outcomes and enabling practitioners to overcome physician supply shortages, there is an urgent need to explore new pharmacologic therapies that target mechanisms of neuro-ophthalmic degeneration

This is the second rejection for remestemcel-L, after the FDA first turned down Mesoblasts application in 2020, despite a 9-1 advisory committee vote in its favor

Sales in 2023 were up 3.8% and rose 4% in 2024 and 5.1% in 2025

Tirzepatide generally produces greater weight loss due to its dual mechanism, but some people respond better to semaglutide for reasons not fully understood

When symptoms continue despite these steps, doctors start looking for different strategies